April 16, 2015

Wall Street Journal VC Dispatch

Hydra Biosciences has secured $11 million

Hydra Biosciences has secured $11 million to test a drug that may treat painful diabetic neuropathy. Abingworth, Advanced Technology Ventures, BioVentures Investors and Lilly Ventures participated in the Series E financing